Israel's Eloxx merges with Sevion Therapeutics

Biotech development, photo: Shutterstock
Biotech development, photo: Shutterstock

Eloxx Pharmaceuticals, which is developing therapeutics for genetic diseases caused by non-sense mutations, hopes to raise at least $24 million and then list on Nasdaq.

US company Sevion Therapeutics Inc. (OTCQB: SVON) is buying Israeli drug developer Eloxx Pharmaceuticals Ltd. Under the terms of the agreement, Rehovot-based Eloxx will become a wholly owned subsidiary of Sevion. When the deal is completed, Sevion will change its name to Eloxx Pharmaceuticals Inc. and will apply to have its shares listed for trading on Nasdaq.

Eloxx Pharmaceuticals is a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations. The company was co-founded by CEO Dr. Silvia Noiman and Israeli life sciences venture capital fund Pontifax and is based on technology developed at the Technion Israel Institute of Technology in Haifa, and research led by Prof. Timor Baasov. The technology is licensed from the Technion through its technology transfer company, Technion Research and Development Foundation Ltd.

Founded in 2013, Eloxx, which has raised $8.5 million to date, was named as one of "Globes" most promising startups in 2016.

Under the terms of the agreement, Eloxx shareholders will receive shares of Sevion’s common stock reflecting 70% of Sevion’s share capital. The companies expect to raise at least $24 million in private equity investment rounds as a condition prior to completion of the deal.

3-4% of newborns manifest a genetic disease or major birth defect, and about 12% of all mutations reported are caused by nonsense mutation. Non-sense mutations introduce premature stop codons in the reading frame of a gene. Eloxx's lead compound, ELX-02, provides unique opportunity to potentially be the first disease-modifying therapy for treatment of these set of devastating diseases, for which there are no effective treatments.

Dr. Noiman said, “The transaction with Sevion positions Eloxx to become a leading rare disease company with sufficient capital to advance its pipeline of first-in-class small molecule therapeutics through significant value-creating events. We plan to initiate multiple clinical studies for ELX-02, our lead development candidate. Importantly, we anticipate achieving substantial clinical milestones over the course of 2017 and 2018 particularly in our lead clinical programs in cystic fibrosis and cystinosis patients carrying non-sense mutations. ELX-02 has shown pharmacological, pharmacodynamic and physiological effects in several animal models of genetic disease cause by non-sense mutations including Cystic Fibrosis (CF) , Cystinosis, Duchene Muscular Dystrophy (DMD), Rett syndrome and mucoplysaccharidose type I (MPS I).”

Dr. Phillip Frost, the former Teva Pharmaceuticals chairman and OPKO chairman and CEO is a director of Sevion. He said, “We are enthusiastic by the breadth of Eloxx’ technology and pipeline, the quality of the management team and the prospects for Eloxx’ products and technology, particularly its lead compound for the treatment of cystic fibrosis and cystinosis patients carrying non-sense mutations. Based upon its unique capabilities to restore full-length functional proteins in genetic diseases, we expect that Eloxx will establish itself over the coming years as an innovative leader in the development of therapeutics to treat a variety of rare and ultra-rare genetic diseases.”

The executive team of Eloxx Pharmaceuticals will manage the combined Sevion-Eloxx entity, which will be based out of Eloxx Pharmaceuticals’ current corporate offices in Waltham, Massachusetts and Rehovot. The combined entity’s leadership team will consist of Dr. Silvia Noiman, who will serve as CEO and Dr. Pedro Huertas as Chief Medical Officer. The respective Boards of Directors of both companies have approved the proposed transaction.

Shareholders of Eloxx Pharmaceuticals, including Pontifax and Mr. Gilad Shabtai, who hold in the aggregate approximately 81% of its voting shares to date have entered into agreements in support of the proposed transaction.

While these agreements assure the approval of the transaction, all Eloxx Pharmaceuticals shareholders will be asked to vote on the transaction at a meeting of shareholders to be held shortly following signing of the agreement for the acquisition. The transaction is expected to close on or before December 31 2017.

Pearl Cohen represented Sevion Therapeutics Inc. in this transaction. Senior Partner Yael Baratz, Chair of the Corporate and Licensing Group, together with Partner Michael Nussbaum, led the deal and handled the Corporate side. Senior Partner Mark Cohen, Chair of the Life Sciences Practice Group was patent counsel for Sevion on its intellectual property diligence matters.

Published by Globes [online], Israel business news - www.globes-online.com - on June 2, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

Biotech development, photo: Shutterstock
Biotech development, photo: Shutterstock
Greenfield Partners team credit: Eyal Toueg Greenfield Partners closes $400m third fund

The funds were raised from institutional investors in Israel, the US, Europe and Asia and brings the total funds under management to more than $1 billion.

Blockaid founders Ido Ben-Natan and Raz Niv credit: Liron Weissman Israeli onchain security co Blockaid raises $50m

Blockaid protects the largest companies building onchain, including Coinbase, Metamask, Stellar, Uniswap, and World App.

Air Haifa  credit: ATR Air Haifa to launch Paphos flights

New Israeli airline Air Haifa will launch a new route between Haifa and Paphos in Cyprus on April 3, 2025 with six weekly flights.

Bladeranger Deepsolar credit: PR Bladeranger divests Deepsolar to Painreform in strategic move

Deepsolar, acquired by Bladeranger in early 2023, is a sophisticated software solution designed to optimize the management of photovoltaic solar energy fields.

Traffic jam on the Ayalon Highway in Tel Aviv credit: Shutterstock Tender issued for operating Tel Aviv congestion charge

Minister of Transport Miri Regev has dropped her opposition to the project, reportedly in exchange for financing railways to Kiryat Shmona and Eilat.

Ilya Sutskever credit: Cadya Levy Ilya Sutskever's SSI raising money at $30b valuation - report

The AI startup founded last year by OpenAI founder and former chief scientist Ilya Sutskever, is in talks to raise money at a company valuation of over $30 billion, "Bloomberg" reports.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al stock still rising despite return of foreign airlines

The Israeli carrier's share price has risen 35% since the start of the year and some analysts predict further gains.

NIS 200 bills credit: Tali Bogdanovsky Reduction in cash holdings after NIS 200 bill abolishment talk

Since September 2024 there has been a dramatic decline in the number of NIS 200 bills held by the public relative to the number of NIS 100 bills, according to Bank of Israel data.

Teva CEO Richard Francis credit: Elad Malka Teva CEO responds to 25% share price fall

Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.

Holon employment bureau credit: Eyal Izhar Unemployment in Israel fell in January

The unemployment rate in Israel fell to 2.6% in January 2025, after seasonal adjustment, from 2.7% in December 2024, the Central Bureau of Statistics reports.

Dizengoff Center credit: Guy Hamoy Israel's economy grew 1% in 2024, above expectations

This figure reflects negative GDP per capita growth of 0.3%, because of population growth last year, the Central Bureau of Statistics reports.

Shalev Hulio and Sebastian Kutz credit: Pini Siluk and Dominic Butzmann Israeli co Dream Security raises $100m at $1.1b valuation

The company, which protects national infrastructures, was founded by former spyware company NSO Group CEO Shalev Hulio, former Austrian Chancellor Sebastian Kurz and Gil Dolev.

CyberArk CEO Matt Cohen and founder and executive chairman  Ehud Mokady  credit: PR $20b CyberArk becomes Israel's second most valuable co

The cybersecurity company's share price has almost tripled in value in the past three years.

Israel Tax Authority Head Shay Aharonovich credit: Yossi Zamir Israel Tax Authority set to publish voluntary disclosure plan

The latest procedure, delayed for over a year, will not include an anonymous track but will have a fast track for unreported cryptocurrency assets.

Tel Aviv credit: Shutterstock Meitav sees Israel housing prices falling

More Israeli households are expected to prefer renting a home rather than buying their own apartment and the consequences will be negative, Meitav investment house chief economist Alex Zabezhinsky predicts.

Sasha Troufanov credit: IDF Spokesperson Amazon CEO welcomes release of employee Sasha Troufanov

Andy Jassy said that Amazon has not commented publicly on the hostages for fear that it would negatively impact their ability to be released, or how they were treated in captivity.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018